Skip to main content
Ovation Science Inc. logo

Ovation Science Inc. — Investor Relations & Filings

Ticker · OVAT LEI · 549300A1P7L8HTTQXY56 CSE Professional, scientific and technical activities
Open in API
Filings indexed 114 across all filing types
Latest filing 2026-01-14 Regulatory Filings
Country CA Canada
Listing CSE OVAT

About Ovation Science Inc.

https://ovationscience.com/

Ovation Science Inc. is a research and development company specializing in advanced topical and transdermal product formulations. The core technology is Invisicare®, a patented, high-performance drug delivery system engineered to enhance the penetration and efficacy of active ingredients, particularly cannabis and hemp-derived cannabinoids (CBD, THC, CBN, CBG). Ovation utilizes pharmaceutical protocols to develop these formulations. Its primary business model involves licensing the Invisicare® technology and proprietary formulations to international partners for manufacturing and market distribution. The company also distributes finished topical CBD products under proprietary brands, such as the Invibe® MD wellness line and ARLO CBD Beauty anti-aging line, all leveraging the unique delivery capabilities of Invisicare®.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a 'Material Change Report' (Form 51-102F3), which is a standard regulatory filing in Canada used to disclose significant events or changes in a company's business. Since it does not fit into specific categories like M&A, financial reports, or director dealings, and serves as a formal regulatory disclosure of a material event (patent issuance), it falls under the 'Regulatory Filings' category.
2026-01-14 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the grant of 2,200,000 stock options to directors and officers of Ovation Science Inc. This type of corporate action, involving the issuance of equity-based compensation or capital changes, falls under the category of share issues or capital changes. While it involves directors, it is not a report of a personal trade (DIRS) but rather a company-level grant of options, making 'SHA' (Share Issue/Capital Change) the most accurate classification.
2026-01-13 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a non‐brokered private placement financing (new equity units and warrants) to raise capital for the company. This is a fundraising activity and capital structure update, fitting the “Capital/Financing Update” category.
2025-09-30 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Notice of Meeting and Record Dates for the Issuer’s upcoming Annual General Meeting, filed via SEDAR+ to regulators and exchanges. It does not contain AGM materials or full proxy statements, nor does it announce vote results or dividends. It is essentially a filing notice without fitting any more specific category; thus it falls under the general Regulatory Filings (RNS) category.
2025-09-25 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing a strategic license expansion agreement with Planet 13 to bring topical cannabis products into Florida. It does not present financial results, dividends, share transactions, a formal report, or a capital raising, nor is it a management/earnings call transcript, regulatory legal proceeding, M&A, or other specific category. It is a general business update and falls into the fallback category for miscellaneous regulatory announcements.
2025-07-29 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a filled Form 13-501F1 “Participation Fee Management Certification” submitted to the Alberta Securities Commission. It is a statutory regulatory form for fee payment, not an annual report, earnings release, board change, share transaction, or other specialized report. It does not announce or attach another report, so it is not an RPA. This falls under the general regulatory filing category (RNS).
2025-05-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.